Strides Arcolab’s arm gets US FDA nod for Paclitaxle injection

30 Sep 2011 Evaluate

Onco Therapies, a division of Agila, which is a wholly owned subsidiary of Strides Arcolab, has received US Food and Drug Administration (FDA) approval for Paclitaxle injection USP, 6mg/ml packaged in 30mg/ml, 100mg/ml and 300mg/ml multiple dose vials.

Paclitaxle injection is among the products in the drug shortage list of the America Society of Health-System Pharmacists and the USFDA. The US market of Paclitaxle is about $46 million. The company will launch the product immediately.

The company has also got tentative approval for Oxaliplatin injection which has a US market of about $1.4 billion.

Recently, Onco Therapies received European Union (EU) approval for Oxaliplantin Injection 5mg/ml (10ml, 20ml and 40ml). This is the second European approval out of the 22 filings made by OTL in the year 2010 for products which have a combined market value of over $5 billion.

Strides Arcolab is global pharmaceuticals company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with emphasis on sterlite injectables.

Strides Pharma Scien Share Price

910.45 -27.95 (-2.98%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×